Hannah Brendan
Known title: Chief Business OfficerCIK: 0001929422
Hannah Brendan's purchase track record
Hannah Brendan has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/19/2024 | QNCX | $24K | +186.9% | +131.2% | +9.3% |
| 8/8/2023 | QNCX | $88K | -25.3% | +5.7% | +10.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| QNCX | ▲ Buy | Option Exercise | 2,271 | $1K | 12/5/2025 | View on chart |
| QNCX | ▲ Buy | Option Exercise | 25,280 | $24K | 12/5/2025 | View on chart |
| QNCX | ▲ Buy | Grant | 37,736 | $45K | 6/18/2025 | View on chart |
| QNCX | ▲ Buy | Open Market | 23,565 | $15K | 8/21/2024 | View on chart |
| QNCX | ▲ Buy | Open Market | 2,280 | $1K | 8/21/2024 | View on chart |
| QNCX | ▲ Buy | Open Market | 5,000 | $3K | 8/21/2024 | View on chart |
| QNCX | ▲ Buy | Open Market | 2,500 | $2K | 8/20/2024 | View on chart |
| QNCX | ▲ Buy | Open Market | 3,424 | $2K | 8/20/2024 | View on chart |
| QNCX | ▲ Buy | Open Market | 2,155 | $1K | 8/19/2024 | View on chart |
| QNCX | ▲ Buy | Option Exercise | 56,061 | $31K | 6/4/2024 | View on chart |
| QNCX | ▲ Buy | Open Market | 71,762 | $88K | 8/8/2023 | View on chart |
| QNCX | ▲ Buy | Grant | 16,224 | — | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Quince Therapeutics LAM-001 Progress; Analyst Targets $70
Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.
Quince Therapeutics LAM-001 Progress; Analyst Targets $70. Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.